American Century Mid Cap Growth Impact ETF

Cloudflare and Stripe Launch Open Protocol for Autonomous AI Agent Configuration and Payments

KLA CEO Michael Hsing Sells 39k Shares for $58.03M

JLens Urges Cloudflare Shareholders to Vote Against Directors Over Content Control Failures

MSCI Inc Reports Earnings Beat, Analysts Issue Moderate Buy Rating with $692.70 Avg Target

TD Cowen and Barclays Analysts Upgrade Vertiv to Buy with $387 Target

Cloudflare CAO Janel Riley Sells Shares and Exercises Options

Armada Partners with Johnson Controls to Build Modular Data Centers in Arizona, Creating 500 Jobs and Securing $230M Funding

MSCI CEO Henry A. Fernandez Invests $2.17M to Buy 4,000 Shares

Johnson Controls Intl President Todd M. Grabowski Sells 4,274 Shares for ~$623k

Vertiv Launches New Products to Support Nvidia Rubin Platform as Liquid Cooling Becomes AI Infrastructure Necessity

Wells Fargo Analyst Maintains Buy Rating on Vistra Corp with $259 Target

L & S Advisors Reduces Stake in Vertiv Holdings by 77.6%, Holding Drops to 14,876 Shares

Loop Capital Initiates Coverage on Vertiv Holdings Co with 'Buy' Rating, $500 Price Target

Johnson Controls Expands Denmark Facility for Data Center Demand, Q2 Revenue $6.14B, 2028 Target $27B

Virginia Retirement System Increases MSCI Stake by 1912% in Q4, Executives Sell Shares

NewEdge Wealth LLC and Other Institutions Increase Holdings in Vertiv

Johnson Controls Completes Acquisition of Alloy Firm

Citibank Raises Target Price for Vertiv Holdings to $414 and Maintains Buy Rating

Indonesian Stock Exchange Chairman Says MSCI Announcement Lowers Market Uncertainty

Johnson Controls Vice President Schlitz Lei Zhang Sells $12.51 Million Shares

Co-Diagnostics

Liminatus Pharma

NewGenIvf

Agape ATP

PicoCELA

Tradr 2X Long RGTI Daily ETF

Tradr 2X Long QBTS Daily ETF

Defiance Daily Target 2X Long RGTI ETF

Wheeler Real Estate

Sunshine Biopharma

MCOW

MIDE

SPMD

ProShares UltraShort MidCap400 ETF (MZZ) shares have entered oversold territory, trading as low as $6.145, with a Relative Strength Index (RSI) of 27.9. This indicates heavy selling may be exhausting, presenting potential buying opportunities. The 52-week range for MZZ is $6.145 to $10.5194, and shares are down about 3.8% for the day. In contrast, the S&P 500's RSI is at 77.7, suggesting a significant difference in market momentum.

nasdaq

Pro Ultsht M-Cp 400

Pacer S&P MidCp 400 Qul FCF Arstcrts ETF

Xtrackers S&P MidCap 400 ESG ETF

SPDR Portfolio S&P 400 Mid Cap ETF

ProShares UltraShort MidCap400 (MZZ) Enters Oversold Territory

DTCR

IVOO

DigitalOcean Holdings will join the S&P MidCap 400 on April 9, 2026, impacting its capital allocation and trading profile. This move may influence perceptions of growth and risk, particularly in relation to AI-driven growth and high debt levels. Analysts project $1.3 billion in revenue and $182 million in earnings by 2028, but caution exists around churn and pricing pressures. The stock's fair value is estimated at $59.58, indicating a potential downside. Investors are encouraged to consider both optimistic and cautious narratives regarding DigitalOcean's future.

Simplywall

Global X Data Center & Dgtl Infrs ETF

iShares Core S&P Mid Cap

SPDR S&P Midcap 400

Digitalocean

ISHRS S&P M-Cap 400/Barra Growth

ISHRS S&P Glb It

Franklin Exponential Data ETF

VG S&P M-Cap 400

Pacer Data & Infrastructure Real Estate ETF

iShares US Digital Infrastructure and Real Estate ETF

Global X Cloud Computing ETF

Proshares Big Data Refiners ETF

Does DigitalOcean (DOCN) Entering the S&P MidCap 400 Reframe Its Balance of Growth and Risk?

AVUV

IWMI

ITWO

In March 2026, global markets are experiencing mixed performances due to geopolitical tensions and fluctuating energy prices. While large-cap stocks are under pressure, small- and mid-cap indexes like the S&P MidCap 400 and Russell 2000 show resilience, presenting opportunities for investors. A list of top 10 undiscovered gems with strong fundamentals includes companies like Aurisco Pharmaceutical, Qingdao NovelBeam Technology, and Shandong Sacred Sun Power Sources, all demonstrating robust financial health and growth potential. Investors are encouraged to explore these stocks for long-term growth amidst economic uncertainties.

- In March 2026, global markets experienced mixed performances due to geopolitical tensions and fluctuating energy prices, with small- and mid-cap stocks showing resilience.  
- Several companies, classified as "undiscovered gems," exhibited strong fundamentals despite market pressures, with Aurisco Pharmaceutical and Qingdao NovelBeam Technology highlighting robust earnings growth and attractive valuations.  
- The article emphasizes the importance of identifying stocks with strong fundamentals for potential long-term growth amid economic uncertainties.

Avantis U.S. Small Cap Value

ISHRS Russ 2000 Val

NEOS Russell 2000 High Income ETF

Vanguard Russell 2000 Growth

Vanguard Russell 2000

ProShares Russell 2000 High Income ETF

ProShares Ultra Russell2000 ETF

SPDR S&P 600 S-Cp Val

Pro Rsl 2000 Dvd Grw

Avantis US Large Cap Value ETF

VG Value

Schw Us L-Cp Grw

VG Growth

VG S&P M-Cap 400 Val

Vanguard Russell 2000 Value

VG Mga Cap 300 Grw

iShares Russell 2000

iShares Core S&P US Growth

VG Mid-Cap Val

Invesco QQQ Trust

VG S-Cp Grw

ISHRS Russ 2000 Growth

Global X Russell 2000 ETF

ISHRS Russ 1000 Growth

Undiscovered Gems in Global Markets for March 2026

ProShares Ultra MidCap400 ETF (MVV) shares fell below their 200-day moving average of $70.25, trading as low as $69.07, down 2.8% on the day. The 52-week range for MVV is $42.64 to $83.01, with the last trade at $69.17. The performance chart indicates a significant drop below the moving average, highlighting a notable trend in the ETF's trading activity.

Ultr M-Cp 400 Pro

ProShares Ultra MidCap400 Breaks Below 200-Day Moving Average - Notable for MVV

iShares Core S&P Mid-Cap ETF (IJH) has declared a quarterly distribution of $0.1569, with a 30-Day SEC Yield of 1.23% as of February 28. The distribution is payable on March 20 for shareholders of record on March 17, with an ex-dividend date also on March 17. The ETF, valued at $112 billion, is gaining attention as large-cap stocks maintain a historic premium over smaller peers.

IShares Core S&P Mid-Cap ETF declares quarterly distribution of $0.1569

SOLS

Solstice Advanced Materials (NasdaqGS:SOLS) has been added to the S&P MidCap 400 during the March 2026 quarterly rebalancing, highlighting its growing significance in the AI supply chain. The stock, currently priced at $72.17, has seen a 46.4% year-to-date return, despite a recent 8.1% decline. This inclusion may influence trading volumes and ownership as index funds adjust their holdings. Analysts have set a target price of $83.83, indicating potential undervaluation. Investors are advised to monitor the company's performance and market positioning closely.

Solstice Advanced Materials

ISHRS S&P M-Cap 400/Barra Val

Solstice Joins S&P MidCap 400 As AI Supply Chain Valuation Story Grows

Maybe it's time for mid-cap stocks to finally get their due. This ETF compensates investors while they wait for that to happen.

Pro S&P Mid 400 Dvd

Wtree Us M-Cp Dvd

This dividend ETF you haven't heard of is springing to life

Arrowhead Pharmaceuticals reported a significant profit surge in Q1 2026, with sales reaching $264.03 million and net income of $30.81 million, a stark contrast to the previous year's $2.5 million in sales. The company was also added to the S&P MidCap 400, indicating a shift in its financial profile. While this move may enhance liquidity and broaden the shareholder base, risks remain tied to clinical trials and partner-dependent revenue. Analysts have varying forecasts for Arrowhead's future revenue, with some projecting a decline, highlighting the uncertainty surrounding its investment narrative.

SPDR S&P Biotech

iShares US Pharma

ArrowHead Pharma

ALPS Medical Breakthrough

Invesco Nasdaq Biotechnology ETF

Invesco Biotechnology & Genome ETF

Ark Genomic Revolution ETF

First Trust NYSE Arca Biotech Index Fd

Proshares Ultra Nasdaq Biotech

iShares Biotechnology ETF

VanEck Biotech ETF

Health Care Select Sector SPDR

VG Health

Is Arrowhead’s Profit Surge and S&P MidCap 400 Move Altering The Investment Case For Arrowhead Pharmaceuticals (ARWR)?

The stock market is shifting focus from tech giants, known as the "Magnificent Seven," to small and mid-cap companies, which have outperformed with gains of 6-9% this year. The tech giants, facing valuation compression due to heavy investments in AI infrastructure, have seen their collective index drop over 3.2% year-to-date. While the broader market shows resilience with record high valuations, concerns grow over the sustainability of cash flow as companies invest heavily in future technologies. Valuation multiples for the tech leaders have compressed by 15-20%, reflecting investor caution regarding long-term returns.

Talkmarkets

From Superstars To The Bench: The Market Rediscovers Team Sports

As global markets face economic uncertainties, investors are focusing on small-cap stocks for potential opportunities. Key indices like the S&P MidCap 400 and Russell 2000 have seen declines. The article highlights ten undiscovered gems with strong fundamentals, including companies like Limin Group, Jiangyin Electrical Alloy, and Beijing Zhidemai Technology, showcasing their financial health and growth potential. These companies exhibit resilience and promising earnings growth, making them attractive options for investors looking to diversify their portfolios in a volatile market.

ProShares UltraShort R2000 ETF

Direxion Small Cap Bear 3X

Direxion Small Cap Bull 3X

Undiscovered Gems in Global Markets To Explore This January 2026

American Century Mid Cap Growth Impact ETF(MID.US)